ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

SEER Program Challenged, Will Face Review

May 9, 1980

Cancer Groups Propose Six Characteristics Of Next FDA Head.

December 19, 2008

In Brief: Beahrs, Murphy, Quan Honored By SSO; AACR Award Mulligan, Wiggler, Sporn, Witte

March 29, 1991

CHOP Training Conference Planned

January 23, 1981

The Cancer Letter To End Print Edition In January

November 20, 2009

Reauthorization Bill Ready For Senate Floor; Report to Panel Makes Clear Why Renewal Needed

April 22, 1988